Physician profile
Aran Degenhardt
NPI 1649260001
$445.92
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $129 · 2021: $16.06.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.11 | 2019-2020 | |
| Adlon Therapeutics L.P. | $56.35 | 2019-2020 | |
| Gilead Sciences, INC. | $45.93 | 2019 | |
| Abbvie INC. | $42.96 | 2019-2020 | |
| Bioventus LLC | $28.08 | 2019 | |
| Ironshore Pharmaceuticals INC. | $20.00 | 2020 | |
| Phadia US INC. | $16.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.88 | 2020 | |
| Optinose US, INC. | $14.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aran Degenhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.